Differential Bio combines advanced microbiology, laboratory automation, and artificial intelligence to improve the optimization and scaling of bioprocesses. The virtual platform uses scale-down experiments and AI-driven models to optimize growth conditions and production processes for microbial systems. This is designed to increase efficiency in bioproduction and improve results in terms of yield, costs, and product quality.
In the long term, the company aims to become the standard for in-silico bioprocess optimization as “The Organism Modeling Company” – from early research and development phases through to industrial production.
Differential Bio addresses bioproduction challenges
Bioproduction, in which biological systems such as microbial cells are used to manufacture everything from food ingredients to pharmaceuticals, offers a sustainable alternative to conventional, often petroleum-based production processes. Yet despite its potential, the industry faces a major hurdle. Scaling bioprocesses from the lab to the industrial level is slow and often prohibitively expensive.
Christian Spier, CEO of Differential Bio, explains:
“Bioproduction is the key to a regenerative future, but scaling these processes remains a major bottleneck for the industry. But we’re here to change that by equipping bioproducers with cutting-edge tools to reduce development times and costs and bring bio-based products to market faster than ever before.”
Investors bet on forward-looking technology
The funding round was led by Ananda Impact Ventures and ReGen Ventures. Additionally, Carbon13, Climate Capital, Better Ventures, CDTM Ventures, and a group of angel investors participated in the investment.
Bernd Klosterkemper, partner at Ananda Impact Ventures, highlights the potential of the technology:
“The Differential team immediately convinced us with its extraordinary combination of solid technical expertise, innovative scientific approach, and visionary commitment to delivering impactful solutions at scale. We believe their technology will redefine bioproduction by enabling faster and more efficient scaling of bio-based processes and accelerating the global transition to a sustainable, green, and circular economy.”
And Tom McQuillen, partner at ReGen Ventures, adds:
“Bioproduction is hindered by a scaling crisis. By applying machine learning based on extensive phenotypic and bioprocess data, Differential has the potential to redefine bioproduction at scale by enabling incremental reductions in costs and time to commercialization.”
With the fresh capital, the startup plans to further develop its platform, expand its team, and acquire new customers in the food, cosmetics, and specialty chemicals sectors.
